Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

Multifocal contact lenses for ageing eyes

25th September 2017

Our eyes stiffen gradually throughout our adult lives. Generally, it isn’t until people reach their forties or older, that they start to notice the effects of this. The stiffening of the lens in the...

Read more

National Eye Health Week: Sight after sixty

22nd September 2017

As part of National Eye Health Week, we are highlighting key eye care advice for various groups. Today we're sharing Vision Matters' advice on the ageing eye, sight after sixty. Our visual ...

Read more

National Eye Health Week: Children’s eye sight

19th September 2017

As part of National Eye Health Week we are encouraging people to ensure they're giving their eyes the best possible care. Today we're looking at children's vision. Your child’s sight is precious....

Read more

Gillian Bruce top performing masters student

05th September 2017

It goes without saying that we’re incredibly passionate about eyes at Cameron Optometry. At least one of our team is always in the midsts of some form of eye-related studies, looking for ways to gai...

Read more